Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy.
10.1016/j.apsb.2024.10.006
- Author:
Danni LIU
1
;
Yaoqi WANG
1
;
Qi SUN
1
;
Dong MEI
2
;
Xiaoling WANG
2
;
Yan SU
2
;
Jie ZHANG
1
;
Ran HUO
1
;
Yang TIAN
1
;
Siyu LIU
1
;
Shuang ZHANG
1
;
Chunying CUI
1
Author Information
1. School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
2. Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.
- Publication Type:Journal Article
- Keywords:
Antitumor;
Ferritin;
Ferroptosis;
Gene silencing;
Glutathione peroxidase 4;
Iron homeostasis;
Lipid peroxidation;
siRNA
- From:
Acta Pharmaceutica Sinica B
2025;15(1):526-541
- CountryChina
- Language:English
-
Abstract:
Ferroptosis has received great attention as an iron-dependent programmed cell death for efficient cancer therapy. However, with the accumulation of iron in tumor cells, the antioxidant system is activated by reducing glutathione (GSH) with glutathione peroxidase 4 (GPX4), which critically limits the ferroptosis therapeutic effect. Herein, an iron and GPX4 silencing siRNA (siGPX4) co-encapsulated ferritin nanocage (HFn@Fe/siGPX4) was developed to enhance ferroptosis by disruption of redox homeostasis and inhibition of antioxidant enzyme synergistically. The siGPX4 were loaded into the nanocages by pre-incubated with iron, which could significantly improve the loading efficiency of the gene drugs when compared with the reported gene drug loading strategy by ferritin nanocages. And more iron was overloaded into the ferritin through the diffusion method. When HFn@Fe/siGPX4 was taken up by human breast cancer cell MCF-7 in a TfR1-mediated pathway, the excess iron ions in the drug delivery system could for one thing induce ferroptosis by the production of reactive oxygen species (ROS), for another promote siGPX4 escaping from the lysosome to exert gene silencing effect more effectively. Both the in vitro and in vivo results demonstrated that HFn@Fe/siGPX4 could significantly inhibit tumor growth by synergistical ferroptosis. Thus, the developed HFn@Fe/siGPX4 afforded a combined ferroptosis strategy for ferroptosis-based antitumor as well as a novel and efficient gene drug delivery system.
